About The Study: Patients with post–COVID-19 mRNA vaccination myocarditis, contrary to those with post–COVID-19 myocarditis, show a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months. However, affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge.
About The Study: Patients with post–COVID-19 mRNA vaccination myocarditis, contrary to those with post–COVID-19 myocarditis, show a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months. However, affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge.
Corresponding Authors: To contact the corresponding authors, email Laura Semenzato, MSc (laura.semenzato@assurance-maladie.fr) and Mahmoud Zureik, MD, PhD (Mahmoud.ZUREIK@ansm.sante.fr).
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.16380)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2024 International Society for Pharmacoepidemiology Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
Discover more from Science
Subscribe to get the latest posts sent to your email.
